Evaluation of clinical responders with advanced triple-negative breast cancer from keynote-890 to validate a published CXCR3 gene signature

Active Project Grant Awarded Last action

Award ID
HT94252310999
Recipient
Awarding agency
Obligated
$1,795,499

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 78% complete
Place of performance
Palo Alto, CA 94305, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,795,499 project grant to The Leland Stanford Junior University, doing business as Stanford University, to conduct an evaluation of clinical responders with advanced triple-negative breast cancer from the KEYNOTE-890 study. The purpose of this 4-year project is to validate a published CXCR3 gene signature that may help identify patients likely to respond to certain cancer treatments. As a leading academic institution, Stanford University has a strong track record of undertaking research projects for federal agencies across a range of scientific and technical disciplines, including biomedical sciences, healthcare, and emerging technologies.

Quick answers

Who received award HT94252310999?

HT94252310999 was awarded to The Leland Stanford Junior University by Defense Health Agency (Department of Defense) on September 15, 2023.

How much is award HT94252310999 worth?

$1,795,499 has been obligated on HT94252310999.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login